Latest Articles

Publication Date
Women take endometriosis debate to Westminster - MSN

Women take endometriosis debate to Westminster MSN

Published: April 2, 2026, 10:39 a.m.
Soap star reveals crippling health diagnosis after years of painful symptoms - The Irish Sun

Soap star reveals crippling health diagnosis after years of painful symptoms The Irish Sun

Published: April 2, 2026, 10:02 a.m.
Soap star reveals crippling health diagnosis after years of painful symptoms - thesun.ie

Soap star reveals crippling health diagnosis after years of painful symptoms thesun.ie

Published: April 2, 2026, 10:02 a.m.
Endometriosis, PCOS in women often goes undiagnosed for years - Ideastream

Endometriosis, PCOS in women often goes undiagnosed for years Ideastream

Published: April 2, 2026, 9 a.m.
Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care - irishsun.com

Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care irishsun.com

Published: April 2, 2026, 7:44 a.m.
Augmented reality helps visualise women’s health conditions and prep for surgery at Chelsea and Westminster Hospital - HTN Health Tech News

Augmented reality helps visualise women’s health conditions and prep for surgery at Chelsea and Westminster Hospital HTN Health Tech News

Published: April 2, 2026, 6:59 a.m.
IDEA ultrasound protocol: Accuracy in deep endometriosis - OC Academy

IDEA ultrasound protocol: Accuracy in deep endometriosis OC Academy

Published: April 2, 2026, 5:41 a.m.
My “Normal” Pain: A Surgeon’s Impossible Choice - patrolmedia.co.id

My “Normal” Pain: A Surgeon’s Impossible Choice patrolmedia.co.id

Published: April 2, 2026, 12:38 a.m.
myStoria Closes $1.625M Seed Round Led by Graphite Ventures to Expand Reproductive Health Platform - EIN News

myStoria Closes $1.625M Seed Round Led by Graphite Ventures to Expand Reproductive Health Platform EIN News

Published: April 2, 2026, 12:36 a.m.
Single-Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non-Pregnant, Non-Lactating Premenopausal Female Subjects Under Fasting Conditions.

Elagolix is a short-acting oral gonadotropin-releasing hormone antagonist utilized for treating endometriosis-associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use …

Published: April 2, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!